Back to Search Start Over

Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα

Authors :
Rami Eliakim
Idan Goren
Ariella Bar-Gil Shitrit
Tsachi-Tsadok Perets
Meital Gal-Tanamy
Shomron Ben-Horin
Lev Lichtenstein
Eran Maoz
Eran Zittan
Baruch Ovadia
Natalia Masha Freund
Henit Yanai
Sophy Goren
Michal Navon
Maor H. Pauker
Eyal Shachar
Yifat Snir
Adva Levy-Barda
Joel Alter
Jacob E. Ollech
Dani Cohen
Irit Avni-Biron
Moshe Dessau
Iris Dotan
Michal Werbner
Hagar Banai-Eran
Adi Friedenberg
Noy Krugliak
Hadar Edelman-Klapper
Yelena Broitman
Arie Segal
Aharoni Golan Maya Aharoni Golan
Keren M. Rabinowitz
Publication Year :
2021
Publisher :
Cold Spring Harbor Laboratory, 2021.

Abstract

BackgroundPatients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear.Aimto assess immune responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC).MethodsProspective, controlled, multi-center Israeli study. Subjects enrolled received two BNT162b2 (Pfizer/BioNTech) doses. Anti-spike (S) antibodies levels and functional activity, anti-TNFα levels and adverse events (AEs) were detected longitudinaly.ResultsOverall 258 subjects: 185 IBD (67 treated with anti-TNFα), and 73 HC. After the first vaccine dose all HC were seropositive, while some patients with IBD, regardless of treatment, remained seronegative. After the second dose all subjects were seropositive, however anti-S levels were significantly lower in anti-TNFα treated compared to untreated patients, and HC (pConclusionsIn this prospective study in patients with IBD stratified according to treatment all patients mounted an immune response to two doses of BNT162b2. However, its magnitude was significantly lower in patients treated with anti-TNFα, regardless of administration timing and drug levels. Vaccine was safe. As vaccine immune response longevity in this group may be limited, vaccine booster dose should be considered.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........3411dca8b3b90b74fdf7a93282ca704f
Full Text :
https://doi.org/10.1101/2021.08.22.21262263